What Neogene Therapeutics does

Neogene Therapeutics was a private biotechnology company founded in 2018, headquartered in Amsterdam with US operations, that developed engineered T-cell receptor (TCR) therapies targeting neoantigens for the treatment of solid tumors. The company's core technology centered on redirecting patient T-cells to recognize cancer-specific neoantigens — mutated proteins unique to tumor cells — addressing a significant unmet need in oncology where conventional therapies often fail. Its product portfolio included a TCR-T cell therapy platform using autologous immune cells and personalized neoantigen cancer vaccines designed to stimulate immune responses against individual tumor profiles.

Neogene operated as a pre-commercial, clinical-stage biotech funded entirely by venture capital, raising approximately $125 million across a 2019 seed/early round and a 2020 Series B led by EcoR1 Capital, Jeito Capital, and Syncona Partners. The company had 51-100 employees and no commercial revenue or pricing model; its value was derived from proprietary TCR engineering IP, neoantigen target identification capabilities, and scientific leadership including co-founder Ton Schumacher, a prominent T-cell biology researcher. The intended end users were oncology patients with solid tumors who had exhausted existing treatment options.

In January 2023, AstraZeneca acquired Neogene for $320 million to strengthen its TCR-T therapy capabilities and accelerate solid tumor oncology pipeline development. Post-acquisition, Neogene operates as a subsidiary within AstraZeneca's oncology portfolio, and its standalone commercial trajectory is subsumed by the parent's drug development program.

Name

Neogene Therapeutics

Legal name

Neogene Therapeutics

Website

https://neogene.com

Company type

Private

Founded year

2018

Operating status

Acquired

Headcount range

51–100 employees

Short description

Neogene Therapeutics is a biotech company developing engineered T-cell receptor therapies and personalized neoantigen vaccines targeting solid tumors. Acquired by AstraZeneca in January 2023 for $320 million, it serves oncology patients with limited treatment options.

Ownership category

akta.pro rank

Product category

Cell Therapy / TCR Immunotherapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industries

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK), Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG)

Keywords

• TCR cell therapy
• Neoantigen vaccines
• Cancer immunotherapy
• Solid tumor treatment
• Personalized cell therapy

Headquarters

HQ city

Amsterdam

HQ country

Netherlands

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain

Core offering

Neogene Therapeutics develops engineered T-cell receptor (TCR) therapies and personalized neoantigen-based cancer vaccines designed to redirect patient immune cells to recognize and attack solid tumor cancers. The company's pipeline targets cancer-specific neoantigens—mutated proteins unique to tumor cells—via TCR-engineered T-cells and individualized vaccine constructs for oncology indications.

Product overview

Neogene Therapeutics is a US biotechnology company acquired by AstraZeneca in January 2023 for $320 million. The company specializes in developing T-cell receptor (TCR) therapies and personalized cancer vaccines targeting solid tumors. Its core offerings include neoantigen-based personalized cancer vaccines and TCR-T cell therapies designed to harness the patient's own immune system to recognize and destroy cancer cells.

Differentiator

Problem solved

Functional benefit

Products and services

• T-cell Receptor (TCR) Therapies

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Direct peers

• Adaptimmune: Adaptimmune develops engineered TCR-T cell therapies for solid tumors and is the most direct comparable, having received FDA approval for Tecelra in synovial sarcoma; it competes head-to-head with Neogene in the same modality and indication space.
• Immunocore: Immunocore develops TCR-based therapeutics, including the approved ImmTAC molecule tebentafusp, and pursues TCR candidates against solid-tumor targets—directly comparable to Neogene's TCR platform and neoantigen focus.
• Immatics: Immatics uses TCR-based and TCR-engineered cell therapy approaches (ACTengine, ACTallo) targeting tumor-specific antigens for solid tumors, overlapping directly with Neogene's TCR-T modality and solid-tumor focus.
• TScan Therapeutics: TScan discovers TCRs against neoantigens and develops TCR-T therapies for solid tumors and hematologic malignancies—a close parallel to Neogene's TCR discovery-to-therapy pipeline.
• Neon Therapeutics: Neon (acquired by BioNTech) developed personalized neoantigen vaccines and TCR-T cell therapies—virtually identical in scope to Neogene's dual modality platform and a directly comparable reference point.

Broad incumbents

• BioNTech: BioNTech acquired Neon Therapeutics and runs a sizable personalized neoantigen vaccine and TCR program, operating at much greater scale with overlapping mechanism but broader portfolio scope.
• Moderna: Moderna develops mRNA-based personalized neoantigen cancer vaccines (e.g., mRNA-4157) and is a major peer in the personalized cancer vaccine space, with substantially larger resources and Phase 3 programs.
• Iovance Biotherapeutics: Iovance commercializes tumor-infiltrating lymphocyte (TIL) therapy for solid tumors—an adjacent cell-therapy modality for the same patient population Neogene targets with TCR-T.

Emerging players

• Gritstone bio: Gritstone develops personalized neoantigen cancer vaccines using viral vectors and self-amplifying mRNA, representing a comparable approach to Neogene's vaccine arm with a more focused, smaller-scale operation.
• Allogene Therapeutics: Allogene develops allogeneic CAR-T therapies; while mechanistically different, it is a peer in the engineered T-cell therapy space targeting oncology with a contrasting off-the-shelf approach versus Neogene's autologous TCR-T.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neogene Therapeutics